Yayınlar & Eserler

Yayın Ağı
Makaleler 38
Tümü (38)
SCI-E, SSCI, AHCI (30)
SCI-E, SSCI, AHCI, ESCI (34)
ESCI (3)
Scopus (34)
TRDizin (6)
Diğer Yayınlar (2)

1. Nanoneedle-Based Transdermal Gene Delivery: A Minimally Invasive Strategy for Gene Therapy

AKBUĞA F. J., ARPA M. D., ŞALVA E.
International Journal of Molecular Sciences , cilt.26, sa.13, 2025 (SCI-Expanded, Scopus) identifier identifier

2. Changes in the Phenolic, Melatonin, Sugar Contents and Antioxidant Capacity, Depending on Ripening Stage in Different Cornelian Cherry (Cornus mas L.) Fruits

Uğur Y., Zengin R., Ernim C., Günhan Z. İ., Şalva E., Erdoğan S.
CHEMISTRYSELECT , cilt.9, sa.7, ss.1-7, 2024 (SCI-Expanded, Scopus) identifier

3. A New Gene Therapy Approach by Tenascin-C Genome Editing Induces Apoptosis and Cell Cycle Arrest in Triple Negative Breast Cancer Cells

Bareke H., Salva E., Ozbas Turan S.
Cyprus Journal of Medical Sciences , cilt.8, sa.1, ss.20-26, 2023 (TRDizin) Creative Commons License identifier identifier

4. Chitosan-based delivery of CRISPR-Cas9 plasmid in breast cancer stem cells

Canak Ipek T., Avci-Adali M., ATICI C. E., Salva E., OZBAS TURAN S.
Journal of research in pharmacy (online) , cilt.27, sa.1, ss.86-96, 2023 (Scopus, TRDizin) identifier identifier

5. Antiproliferative properties and evaluation of antioxidant of different cornelian cherry genotypes and analysis of phenolic and sugar compounds by HPLC

UĞUR Y., ŞALVA E., KARAAT F. E., ERDOĞAN S.
Hacettepe Journal of Biology and Chemistry , cilt.51, sa.1, ss.57-70, 2023 (TRDizin) Sürdürülebilir Kalkınma identifier

6. Development of Silica Nanoparticles as a Delivery System for Plasmid-Based Crispr/Cas9

ULTAV G., MAÇ K., KIZILBOĞA S., GÜNDOĞDU V., TONBUL H., ŞALVA E.
Anatolian Journal of Pharmaceutical Sciences , cilt.1, sa.1, ss.33-39, 2022 (Hakemli Dergi)

7. An effective VEGF-siRNA delivery via folic acid decorated and pegylated silica nanoparticles

Ultav G., TONBUL H., ŞALVA E.
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus) identifier

8. Investigation of therapeutic effects in the wound healing of chitosan/pGM-CSF complexes

ŞALVA E., ALAN S., Karakoyun B., Cakalagaoglu F., ÖZBAŞ S., Akbuga J.
BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.58, 2022 (SCI-Expanded, Scopus) identifier

9. EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts

KEHRİBAR D. Y., Emmungil H., BAŞAK TÜRKMEN N., ÇİFTÇİ O., ŞALVA E., Ozgen M.
TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.4, ss.1355-1361, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier

10. Synthesis of New 1-Aryl-2-(3,5-dimethylpyrazol-1-yl)ethanone Oxime Ether Derivatives and Investigation of Their Cytotoxic Effects

ALAGÖZ M. A., KARAKURT A., Hepokur C., ŞALVA E., Onkol T., Ghoneim M. M., et al.
PROCESSES , cilt.9, sa.11, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

11. Evaluation of biological activities of Barbarea integrifolia and isolation of a new glucosinolate derivated compound

Badem M., ŞENER S. Ö., KANBOLAT Ş., Korkmaz N., YILDIRMIŞ S., ÖZGEN U., et al.
ZEITSCHRIFT FUR NATURFORSCHUNG SECTION C-A JOURNAL OF BIOSCIENCES , cilt.76, sa.9-10, ss.375-382, 2021 (SCI-Expanded, Scopus) identifier identifier

12. Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer

Kaban K., Hinterleitner C., Zhou Y., ŞALVA E., KANTARCI A. G., Salih H. R., et al.
CANCERS , cilt.13, sa.10, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

13. Relationship between guanosine triphosphate pathway and tetrahydrobiopterin in gestational diabetes mellitus

Ünüvar S., Melekoğlu R., Şalva E., Acar C., Yaşar Ş.
Journal of Diabetes & Metabolic Disorders , cilt.1, ss.1-6, 2020 (ESCI, Scopus) Sürdürülebilir Kalkınma

14. p-Trifluoroacetophenone Oxime Ester Derivatives: Synthesis, Antimicrobial and Cytotoxic Evaluation and Molecular Modeling Studies

Bozbey İ., SARI S., ŞALVA E., KART D., KARAKURT A.
LETTERS IN DRUG DESIGN & DISCOVERY , cilt.17, sa.2, ss.169-183, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

15. Modulation of the dual-faced effects of miR-141 with chitosan/miR-141 nanoplexes in breast cancer cells

Kaban K., ŞALVA E., Akbuga J.
JOURNAL OF GENE MEDICINE , cilt.21, sa.9, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

16. INVESTIGATION OF THE EFFECT OF VEGFshRNAs CLONED INTO SILENCING PLASMIDS ON VEGF EXPRESSION IN ENDOTHELIAL CELL

Şalva E., Yeşilada E.
International Multidisciplinary Symposium on Drug Research & Development (DRD 2019) , cilt.1, sa.1, ss.313-316, 2019 (Düzenli olarak gerçekleştirilen hakemli kongrenin bildiri kitabı) Creative Commons License

17. Synthesis and cytotoxicity studies on new pyrazole-containing oxime ester derivatives

KARAKURT A., Bozbey İ., USLU H., SARI S., ÖZDEMİR Z., ŞALVA E.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH , cilt.18, sa.6, ss.1315-1322, 2019 (SCI-Expanded, Scopus) identifier

18. Synthesis of triazolylmethyl-linked nucleoside analogs via combination of azidofuranoses with propargylated nucleobases and study on their cytotoxicity

HALAY E., AY E., ŞALVA E., AY K., KARAYILDIRIM T.
CHEMISTRY OF HETEROCYCLIC COMPOUNDS , cilt.54, sa.2, ss.158-166, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

19. In Vitro Dose Studies on Chitosan Nanoplexes for microRNA Delivery in Breast Cancer Cells

Kaban K., ŞALVA E., Akbuga J.
NUCLEIC ACID THERAPEUTICS , cilt.27, sa.1, ss.45-55, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

20. Syntheses of 1,2,3-triazole-bridged pyranose sugars with purine and pyrimidine nucleobases and evaluation of their anticancer potential

HALAY E., AY E., ŞALVA E., AY K., KARAYILDIRIM T.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS , cilt.36, sa.9, ss.598-619, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

21. The Effects to GM-CSF Expression and Fibroblast Proliferation of pGM-CSF Containing Chitosan/PVP Hydrogels

ŞALVA E., Akbuga J.
MARMARA PHARMACEUTICAL JOURNAL , cilt.21, sa.2, ss.228-234, 2017 (ESCI, Scopus, TRDizin) identifier identifier

22. The effects of chitosan/miR-200c nanoplexes on different stages of cancers in breast cancer cell lines

Kaban K., ŞALVA E., Akbuga J.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.95, ss.103-110, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

23. Tocilizumab's effect on cognitive deficits induced by intracerebroventricular administration of streptozotocin in Alzheimer's model

Elcioglu H. K., Aslan E., Ahmad S., ALAN S., ŞALVA E., Elcioglu O. H., et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY , cilt.420, ss.21-28, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

24. In Vitro PDGF-B Gene Silencing Studies and In Vivo Delivery of siRNA to the Rat Kidney Using Chitosan/siRNA Nanoplexes

ŞALVA E., Ozbas Turan S., ALAN S., Akbuga J.
MARMARA PHARMACEUTICAL JOURNAL , cilt.20, sa.3, ss.263-268, 2016 (ESCI, Scopus, TRDizin) identifier identifier

25. Comparison of VEGF gene silencing efficiencies of chitosan and protamine complexes containing shRNA

Erdem-Cakmak F., ÖZBAŞ S., ŞALVA E., Akbuga J.
CELL BIOLOGY INTERNATIONAL , cilt.38, sa.11, ss.1260-1270, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

26. Investigation of the Therapeutic Efficacy of Codelivery of psiRNA-Vascular Endothelial Growth Factor and pIL-4 into Chitosan Nanoparticles in the Breast Tumor Model

ŞALVA E., TURAN S. O., Kabasakal L., ALAN S., Ozkan N., EREN F., et al.
JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.103, sa.3, ss.785-795, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

27. The Development of Ternary Nanoplexes for Efficient Small Interfering RNA Delivery

ŞALVA E., Turan S. O., Akbuga J.
BIOLOGICAL & PHARMACEUTICAL BULLETIN , cilt.36, sa.12, ss.1907-1914, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

28. Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo.

Salva E., KABASAKAL L., EREN F., ÖZKAN N., CAKALAĞAOĞLU F., AKBUGA J.
Nucleic acid therapeutics , cilt.22, ss.40-8, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

29. Honey as a substitute for formalin?

ÖZKAN N., Salva E., CAKALAĞAOĞLU F., TÜZÜNER B.
Biotechnic & histochemistry : official publication of the Biological Stain Commission , cilt.87, ss.148-53, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

30. Increased in vitro Cell Proliferation by Chitosan/pGM-CSF Complexes

Salva E., TURAN S., Akbuga J.
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES , cilt.73, sa.2, ss.131-138, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

31. In vitro silencing effect of chitosan nanoplexes containing siRNA expressing vector targeting VEGF in breast cancer cell lines

Salva E., Akbuga J.
PHARMAZIE , cilt.65, sa.12, ss.896-902, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

32. Chitosan/short hairpin RNA complexes for vascular endothelial growth factor suppression invasive breast carcinoma.

Salva E., KABASAKAL L., EREN F., CAKALAĞAOĞLU F., ÖZKAN N., AKBUGA J.
Oligonucleotides , cilt.20, ss.183-90, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

33. Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis.

KARAKOYUN B., YÜKSEL M., ERCAN F., Salva E., IŞIK I., YEĞEN B.
Digestive diseases and sciences , cilt.55, ss.607-16, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

34. Significance of IL-6 and PAI-1 expression in nucleic-acid based therapy of breast cancer

Cakalagaoglu F., Salva E., Ozkan N., KAYA H., KABASAKAL L., Akbuga J.
VIRCHOWS ARCHIV , cilt.455, ss.103, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

35. Double immunostaining method. What is the significance?

OZKAN N., CAKALAGAOGLU F., Salva E.
VIRCHOWS ARCHIV , cilt.451, sa.2, ss.565, 2007 (SCI-Expanded, Scopus) identifier

36. Effect of FK506 in experimental glomerulonephritis: Light microscopic and ultrastructural study

CAKALAPAOGLU F., OZKAN N., Salva E., ARBAK S., USLU B.
VIRCHOWS ARCHIV , cilt.451, sa.2, ss.513-514, 2007 (SCI-Expanded, Scopus) identifier

37. The staining methods of chitosan as a natural biopolymer

Salva E., OZKAN N., CAKALAGAOGLU F., KARAKOYUN B., AKBUGA J.
VIRCHOWS ARCHIV , cilt.451, sa.2, ss.539-540, 2007 (SCI-Expanded, Scopus) identifier

38. The effects in skin wound healing and cell proliferation of the plasmid DNA encoding GM-CSF and chitosan

Salva E., OZKAN N., CAKALAGAOGLU F., KARAKOYUN B., AKBUGA J.
VIRCHOWS ARCHIV , cilt.451, sa.2, ss.565, 2007 (SCI-Expanded, Scopus) identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 31

1. Identification Cytotoxicity and Wound Healing Effects of Various Extracts of Sanguisorba minor Scop. Seeds

TORUN Z., ULTAV G., ŞALVA E.
73rd International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA), jointly with Italian Society of Phytochemistry (SIF), Napoli, İtalya, 31 Ağustos 2025, ss.459, (Özet Bildiri)

2. INVESTIGATION CYTOTOXICITY AND WOUND HEALING OF ACHILLEA BIEBERSTEINII EXTRACTS

TORUN Z., ULTAV G., ŞALVA E.
The 11th International Mediterranean Symposium on Medicinal and Aromatic Plants, Rimini, İtalya, 06 Mayıs 2025, ss.75, (Özet Bildiri)

3. Silica Nanoparticles as Drug and siRNA Delivery System

ULTAV G., TONBUL H., ŞALVA E.
3rd International Conferance on Materials Science and Nanotechnology, Roma, İtalya, 3 - 07 Ekim 2022, (Özet Bildiri)

4. Kızılcık Meyvelerinin Ham, Yarı-Olgun Ve Olgun Dönemlerindeki Biyokimyasal Değişimlerinin İncelenmesi

UĞUR Y., Yaman R., Ernim C., Günhan Z. İ., ŞALVA E., ERDOĞAN S.
10. Ulusal Analitik Kimya Kongresi, Muğla, Türkiye, 7 - 11 Eylül 2022, ss.94, (Özet Bildiri)

5. “Kızılcık Meyvelerindeki Fenolik Bileşiklerin Olgunlaşma Periyodundaki Değişimi Ve Sitotoksik Etkilerinin Araştırılması

Uğur Y., Yaman R., Ernim C., Günhan Z. İ., Şalva E., Erdoğan S.
Analitik Kimya Kongresi, Muğla, Türkiye, 7 - 11 Kasım 2022, ss.92-93, (Özet Bildiri) Sürdürülebilir Kalkınma

6. Combination Therapy Approach of Doxorubicin and siRNA with Biodegradable Silica Nanoparticles

ULTAV G., TONBUL H., ŞALVA E.
The 4th International Conference on Graphene and Novel Nanomaterials (GNN 2022), Shenzhen, Çin, 8 - 11 Ağustos 2022, (Özet Bildiri)

7. DETERMINATION OF EFFECTIVE SURFACE MODIFICATIONS OF SILICA NANOPARTICLES AS VEGF-TARGETED siRNA CARRIERS

ULTAV G., TONBUL H., ŞALVA E.
13th International Symposium on Pharmaceutical Sciences (ISOPS), Türkiye, 22 Haziran 2021, (Özet Bildiri)

8. Actively targeted chitosan-based vector for efficient CRISPR-Cas9 mediated Tenascin-C gene editing in triple negative breast cancer

Şalva E.
European Society Gene and Cell Therapy, Hannover, Almanya, 19 - 21 Ekim 2021, ss.105, (Özet Bildiri)

9. The cellular uptake and endosomal escape mechanisms of chitosan-protamine-siRNA nanoplexes for efficient gene transfection and silencing

Şalva E.
BioTürkiye International Biotechnology Congress, İstanbul, Türkiye, 9 - 11 Eylül 2021, ss.156, (Özet Bildiri)

10. EVALUATION AND CHARACTERIZATION OF FOLIC ACID MODIFIED SILICA NANOPARTICLES AS SIRNA CARRIERS

ULTAV G., ŞALVA E., TONBUL H.
3rd International Gazi Pharma Symposium Series (GPSS- 2021), Türkiye, 08 Eylül 2021, (Özet Bildiri)

11. GESTASYONEL DİABETES MELLİTUSTA GUANOZİN TRİFOSFAT SİKLOHİDROLAZ IVE ENDOTELYAL NİTRİK OKSİT SENTAZ GEN EKSPRESYONLARININDEĞERLENDİRİLMESİ

YÜCE H., ŞALVA E., ACAR C., MELEKOĞLU R., ÜNÜVAR S.
1. ULUSLARARASI MALATYA UYGULAMALI BİLİMLER KONGRESİ, 20 - 22 Aralık 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

12. EVALUATION OF GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I AND ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE EXPRESSIONS IN GESTATIONAL DIABETES MELLITUS

YÜCE H., ŞALVA E., ACAR C., MELEKOĞLU R., ÜNÜVAR S.
1. ULUSLARARASI MALATYA UYGULAMALI BİLİMLER KONGRESİ, Malatya, Türkiye, 20 - 22 Aralık 2019, cilt.1, ss.326-327, (Özet Bildiri) Sürdürülebilir Kalkınma

13. Cytotoxic Effects of New Triflouromethyl Oxime Ester Compounds Bearing Imidazole Moiety on Neuroblastoma Cell Line.

BOZBEY İ., ŞALVA E., KARAKURT A.
International Symposium on Pharmaceutical Sciences, 26 - 29 Haziran 2018, (Özet Bildiri)

14. IN VITRO ANTICANCER ACTIVITY OF NEW NAPHTHYL ETHANONE OXIME ESTER DERIVATIVES BEARING PYRAZOLE MOIETY

BOZBEY İ., USLU H., ŞALVA E., KARAKURT A.
12th International Symposium on Pharmaceutical Sciences, ISOPS-12, Ankara, Türkiye, 26 - 29 Haziran 2018, ss.380, (Özet Bildiri)

15. 1-ARİL-2-(3,5-DİMETİLPİRAZOL-1-İL)ETANON TÜREVİ YENİ BİLEŞİKLERİN SENTEZLERİ VE SİTOTOKSİK ETKİLERİNİN ARAŞTIRILMASI

ALAGÖZ M. A., ŞALVA E., KARAKURT A., ÖNKOL T.
V. ULUSAL FARMASÖTİK KİMYA KONGRESİ, Erzurum, Türkiye, 28 Nisan - 01 Mayıs 2018, ss.20, (Özet Bildiri)

16. Some New 1-Aryl-2-(3,5-Dimethylpyrazole -1-il) Ethanon Derivatives: Synthesis, Anticancer Activity and QSAR Study

ALAGÖZ M. A., ŞALVA E., KARAKURT A., ÖNKOL T.
3rd INTERNATIONAL TURKIC WORLD CONFERENCE ON CHEMICAL SCIENCES AND TECHNOLOGIES, Baku, Azerbaycan, 10 - 13 Eylül 2017, ss.88, (Özet Bildiri)

17. Comparison of short and long siVEGF/encapsulating chitosan nanoparticles in breast cancer cell lines

CÖMEZ B., Akbuga J., ŞALVA E.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, İtalya, 18 - 21 Ekim 2016, cilt.27, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

18. The investigation of effects to cell proliferation and adsorption of new ternary and binary scaffolds

Sirkeci A., ŞALVA E., TURAN S., Akbuga J.
Conference on Changing the Face of Modern Medicine - Stem Cells and Gene Therapy, Florence, İtalya, 18 - 21 Ekim 2016, cilt.27, (Özet Bildiri) identifier

19. Tumor Inhibition by Using Chitosan: siRNA PDGFR-beta in Breast Cancer Model of Rat

Akbuga J., Turan S. O., ŞALVA E., Ozkan N., KABASAKAL L., Alan S.
19th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, Kiribati, 4 - 07 Mayıs 2016, cilt.24, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

20. Lapatinib sinovyal fibroblastlardan matriksmetalloproteinazların salınımını baskılar

ÖZGEN M., emmungil h., ŞALVA E., BAŞAK N., ÇİFTÇİ O.
XVI. ULUSAL ROMATOLOJİ KONGRESİ, Türkiye, 29 Ekim - 01 Kasım 2015, (Özet Bildiri)

21. The effect of tumor suppressive miR-200c and miR-141 optimization in breast cancer cell lines.

KABAN K., ŞALVA E., AKBUGA J.
11th Annual Meeting of the Oligonucleotide Therapeutics Society, Leiden, Hollanda, 11 - 14 Eylül 2015, ss.59, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

22. PDGF-D Inhibition by Using Chitosan: siRNA Complexes in Breast Cancer Model of Rat

Akbuga J., Ozbas-Turan S., KABASAKAL L., Salva E., Ozkan N.
18th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Louisiana, Amerika Birleşik Devletleri, 13 - 16 Mayıs 2015, cilt.23, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

23. Co-Delivery of VEGF siRNA and IL-4 into Chitosan Nanoparticles in Breast Tumor Model of Rat

ŞALVA E., Ozbas-Turan S., KABASAKAL L., EREN F., Alan S., Ozkan N., et al.
16th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Utah, Amerika Birleşik Devletleri, 15 - 18 Mayıs 2013, cilt.21, (Özet Bildiri) identifier

24. Protamine Containing Chitosan:shRNA Complexes for Silencing of VEGF Expression

Cakmak F. E., Turan S. O., Salva E., Akbuga J.
15th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Pennsylvania, Amerika Birleşik Devletleri, 16 - 19 Mayıs 2012, cilt.20, (Özet Bildiri) identifier

25. Chitosan Mediated VEGF shRNA Transfer for the Treatment of Breast Cancer

Salva E., KABASAKAL L., Ozkan N., EREN F., CAKALAGAOGLU F., Akbuga J.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, İtalya, 22 - 25 Ekim 2010, cilt.21, ss.1411, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

26. Intramuscular Delivery of Antisense Oligonucleotides by Chitosan Nanoparticles

Ozbas-Turan S., Akbuga J., SEZER A., Salva E.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, İtalya, 22 - 25 Ekim 2010, cilt.21, ss.1452-1453, (Özet Bildiri) identifier

27. Chitosan nanoparticles containing shRNA targeting VEGF as cancer therapeutic

Salva E., OZBAS-TURAN S., Akbuga J.
18th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Milan, İtalya, 22 - 25 Ekim 2010, cilt.21, ss.1412-1413, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

28. Expression of MMP2, HPV and ALPHA-1 antichymotrypsin as prognostic markers for squamous cell carcinoma of the larynx

CAKALAGAOGLU F., TUZUNER B., OZKAN N., Salva E., Gergin O., Sari M., et al.
27th International Congress of the International-Academy-of-Pathology, Athens, Yunanistan, 12 - 17 Ekim 2008, cilt.53, ss.211, (Özet Bildiri) identifier

29. Characterization and in vitro silencing effect of chitosan/siRNA complexes

Salva E., Akbuga J.
16th Annual Congress of the European-Society-of-Gene-and-Cell-Therapy, Brugge, Belçika, 13 - 16 Kasım 2008, cilt.19, ss.1158, (Özet Bildiri) identifier

30. Delivery of GM-CSF gene using chitosan complexes

Salva E., ENNELI B., AKBUGA J.
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Türkiye, 24 - 29 Haziran 2006, cilt.273, ss.132, (Özet Bildiri) identifier

31. Development of a novel delivery system for antisense oligonucleotides

ENNELI B., Salva E., AKBUGA J.
31st Congress of the Federation-of-European-Biochemical-Societies (FEBS), İstanbul, Türkiye, 24 - 29 Haziran 2006, cilt.273, ss.132, (Özet Bildiri) identifier
Kitaplar 8

1. Biotechnology applications in clinical trials

BÜYÜKKÖROĞLU G., ŞENEL B., ŞALVA E., ÇALIŞKAN F. B.
Biotechnology in Healthcare, Volume 2: Applications and Initiatives, Debmalya Barh, Editör, Elsevier Academic Press, ss.163-195, 2022

2. Characteristics of Marketed Nanopharmaceutics

ŞALVA E., TONBUL H.
Drug Delivery with Targeted Nanoparticles: In Vitro and In Vivo Evaluation Methods, Çapan, Y., Sahin, A., Tonbul, H., Editör, Jenny Stanford Publishing, ss.705-720, 2021

3. Characteristics of Marketed Nanopharmaceutics

ŞALVA E., TONBUL H.
Drug Delivery with Targeted Nanoparticles: In Vitro and In Vivo Evaluation Methods (1st ed.), Yılmaz Çapan, Adem Sahin, Hayrettin Tonbul, Editör, Jenny Stanford Publishing, ss.705-724, 2021

4. Non viral siRNA and shRNA delivery systems in cancer therapy

ŞALVA E., EKENTOK C., OZBAS-TURAN S., AKBUGA F. J.
RNA Interference, Ibrokhim Y. Abdurakmonov, Editör, Intech, Rijeka, ss.201-222, 2016

5. Hücre ve Moleküler Biyoloji Sözlüğü

GÜLSOY N., ALTINKUT UNCUOĞLU A., AYDIN Y., HASDEMİR M. U., AKBUĞA F. J., ŞALVA E.
Nobel Tıp Kitapevi Yayınları, İstanbul, 2014

6. Physical and transfectional properties of aged pIL-2 loaded chitosan microspheres

OZBAS TURAN S., ŞALVA E., AKBUGA J.
Advances in Chitin Science Vol XIII, Varlamov V., Bratskaya S., Yakovleva ı., Senel S., Editör, Euchis, Saint Petersburg, ss.100-50, 2011

7. Chitosan of nanoparticles containing siRNA targeting VEGF for anti-angiogenic gene therapy

ŞALVA E., OZBAS TURAN S., AKBUGA F. J.
Advances in Chitin Science Vol XIII, Varlamov V., Bratskaya S., Yakovleva ı., Senel S., Editör, Euchıs, Saint Petersburg, ss.201-222, 2011

8. Sağlık Hizmetleri Meslek Yüksekokulu Eğiticilerinde Olması Beklenen Özellikler

ÇAKALAĞAOĞLU F., ÖZKAN N., ŞALVA E.
Geçmişten Geleceğe Sağlık Teknikerliği, GÖZİL R., Editör, Gazi Üniversitesi, Ankara, ss.100-120, 2008
Metrikler

Yayın

81

Yayın (WoS)

49

Yayın (Scopus)

36

Atıf (WoS)

362

H-İndeks (WoS)

12

Atıf (Scopus)

420

H-İndeks (Scopus)

13

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Proje

21

Tez Danışmanlığı

6

Açık Erişim

4
BM Sürdürülebilir Kalkınma Amaçları